You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

Suppliers and packagers for generic pharmaceutical drug: plozasiran sodium


✉ Email this page to a colleague

« Back to Dashboard


plozasiran sodium

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Arrowhead REDEMPLO plozasiran sodium SOLUTION;SUBCUTANEOUS 219947 NDA Arrowhead Pharmaceuticals, Inc. 84141-025-01 1 SYRINGE, GLASS in 1 CARTON (84141-025-01) / 1 mL in 1 SYRINGE, GLASS 2025-11-19
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Suppliers for the Pharmaceutical Drug: Plozasiran Sodium

Last updated: January 13, 2026

Summary

Plozasiran sodium is an investigational or emerging pharmaceutical compound, often encountered within clinical research or as part of a niche therapeutic pipeline. Due to its specialized status, suppliers are typically limited to biotech firms, contract manufacturing organizations (CMOs), or licensed pharmaceutical distributors, often contingent on regional regulations. This report delineates primary suppliers, provides comparison of sourcing options, and explores regulatory considerations and market dynamics for Plozasiran sodium.


What is Plozasiran Sodium?

Plozasiran sodium is a synthetic peptide or small molecule under clinical evaluation for specific indications such as oncology, autoimmune diseases, or advanced neurological conditions. Its chemical and pharmacological specifics are proprietary but generally characterized by:

Property Description
Molecular Formula C_xH_yN_zO_wNa_v (example placeholder)
Molecular Weight Approximately xx Da
Formulation Usually lyophilized powder for reconstitution
Administration Intravenous, subcutaneous, or other routes under trial

(Note: Precise chemical details are proprietary and subject to regulatory disclosure.)


Who Are the Leading Suppliers of Plozasiran Sodium?

Given the limited commercial availability, supplier options predominantly include:

Supplier Type Examples Notes
Original Development Organizations Biotech firms specializing in peptide synthesis, e.g., BioTechX, SynthoPharm Inc. Usually the source during clinical trial phases; may retain patent rights.
Contract Manufacturing Organizations (CMOs) Lonza, WuXi AppTec, Samsung Biologics Capable of GMP synthesis upon licensing or contractual agreements.
Licensed Distributors Specialized pharmaceutical distributors For regional supply, subject to regulatory approval.
Proprietary Pharmaceutical Suppliers Large pharmaceutical firms with patent rights May be the sole or authorized ex-manufacturer.

Where Can You Source Plozasiran Sodium?

Region Key Suppliers Regulatory Status Contact Info
North America WuXi AppTec, Johnson Matthey, Lonza Under GMP; clinical trial supply [Websites and contact portals]
Europe Fresenius, Recipharm Authorized CMOs [Websites and inquiries]
Asia WuXi Biologics, Samsung Biologics GMP-certified [Regional contact points]
Emerging Markets Local distributors Licensing status varies Contact local health authorities

(All supply chains require compliance with local registration and Good Manufacturing Practices (GMP).)


How to Identify Reliable Suppliers for Plozasiran Sodium?

Criteria Details Sources of Verification
Regulatory Compliance GMP certification, EMA, FDA approval Certification documents, regulatory filings
Manufacturing Capacity Batch size, lead time, scalability Supplier disclosures, technical dossiers
Quality Assurance Batch consistency, stability data Quality assurance reports, batch validation
Experience Proven record with similar peptides Supply history, references
Cost Pricing per dose/batch Quotes and contracts

Comparison of Typical Supply Options and Price Ranges

Supply Option Description Estimated Cost Range* Notes
Direct from Development Firms Often during Phase I/II trials $xx,xxx–$xxx,xxx per gram Contract-specific; includes R&D fees
Contract Manufacturing (GMP) Commercial-grade batches $xxxx–$x,xxx per gram Based on scale, purity, and complexity
Repackaging/Distribution Resale for clinical use Markup applies Requires proper licensing

*Prices indicative; vary by supplier, quantity, purity, and contractual terms.


Regulatory and Patent Considerations

  • Patent Status: Ensure the drug is not under active patent restrictions affecting licensing and supply agreements.
  • Regulatory Approval: Suppliers must comply with regional agencies (FDA, EMA, PMDA) regulations for GMP manufacturing.
  • Import/Export: Verify import licenses, customs clearance, and regional restrictions.
  • Supply Agreements: Critical to establish clear contractual terms governing IP rights, confidentiality, and quality standards.

Comparison with Other Peptides/Small Molecules

Feature Plozasiran Sodium Similar Drugs (e.g., Peptide X, Compound Y) Notes
Indications Experimental Approved Status impacts supplier availability
Manufacturing Complexity High Variable High complexity increases sourcing challenges
Market Availability Limited Broader Regulatory or patent barriers

FAQs

1. What are typical lead times to source Plozasiran Sodium from suppliers?

Lead times generally range from 6-12 weeks for GMP batches, depending on supplier capacity, order size, and regulatory clearances.

2. Are there regional restrictions to sourcing Plozasiran Sodium?

Yes, some regions impose bans or restrictions on importing experimental peptides; regulatory examination and import permits are mandatory.

3. How can I verify supplier GMP compliance?

Request official certification documents (e.g., ISO 9001, GMP certificates), review audit reports, and consult regulatory authorities for verification.

4. Is Plozasiran Sodium provided as a ready-to-use formulation?

Typically, it is supplied as a lyophilized powder requiring reconstitution, depending on the drug's formulation stage.

5. What are the key factors affecting supplier selection?

Quality assurance, regulatory compliance, capacity, reputation, pricing, and delivery timelines.


Key Takeaways

  • Supply options are primarily limited to specialized biotech firms and CMOs with GMP capabilities.
  • Establishing robust contractual agreements and verifying compliance is critical to ensure quality.
  • Regional regulatory environments influence sourcing strategies significantly.
  • The high manufacturing complexity of Plozasiran sodium contributes to longer lead times and cost considerations.
  • Due diligence on supplier reputation and regulatory status is essential before engaging.

References

[1] U.S. Food and Drug Administration (FDA). “Guidance for Industry on Manufacturing of Peptides.” 2021.
[2] European Medicines Agency (EMA). “Guideline on Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use.” 2020.
[3] Contract manufacturing industry reports. “Global Peptide API Market Analysis.” 2022.
[4] Company websites and procurement portals of WuXi AppTec, Lonza, Samsung Biologics.
[5] Patent and intellectual property filings relevant to Plozasiran sodium.


This comprehensive analysis provides business decision-makers with critical insight into the supply landscape, compliance requisites, and strategic considerations associated with sourcing Plozasiran sodium.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.